Immix Biopharma Inc., a clinical-stage biopharmaceutical company, has announced accelerated progress in its NEXICART-2 clinical trial for relapsed/refractory AL Amyloidosis. The trial has expanded its national footprint to 18 sites, addressing an unmet need where no FDA-approved drugs currently exist. This expansion is expected to expedite the company's path to submitting a Biologics License Application $(BLA.AU)$ for FDA approval. The NEXICART-2 interim results were presented at the American Society for Clinical Oncology (ASCO) 2025, highlighting the promising advancements in cell therapy for this orphan indication. There is no specific mention of grants or funding obtained by multiple organizations in the announcement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.